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Total metabolic tumor volume (TMTV) is a promising quantitative biomarker for therapy assessment 
and prognosis in Hodgkin Lymphoma affected patients that allows prediction of patient outcome. The 
aim of this study was to evaluate the TMTV reproducibility between different sources of variability 
in tumor delimitation such as SUV‑based thresholds (2.5, 41% and 50%) and software tools (Beth 
Israel plugin (BI) and LIFEx). Effect of contouring procedure both including single and multiple regions 
of interest was also studied in patients with multiple lesions, and optimal cut‑offs for each studied 
method were displayed to compare the effect on prognosis. Strong alikeness in TMTV was found for 
2.5 under software choice. Best accuracy in contouring compared to visual assessment of the disease 
was found for BI multiple ROI and LIFEx single ROI drawing. Similar cut‑offs were found between 
both software for all considered thresholds, but best resemblance and highest cut‑off due to an 
overestimation of the TMTV was found for 2.5 SUV. Our findings suggest that optimal reproducibility 
in TMTV is found for SUV > 2.5 threshold under choice of contouring methodology or software 
tool, meaning that overestimation of the TMTV threshold using 2.5 looks to be preferable than 
underestimation with 41% and 50%.
[18F]FDG PET/CT imaging has been used to assess the total metabolic tumor volume (TMTV) in the clinical 
staging of newly diagnosed Hodgkin  lymphoma1. However, false-positive results have led to the use of new 
methods to face non-specificity of  [18F]FDG uptake and the lack of differentiation between malignancy and 
physiological background. Many methodologies on how to estimate TMTV have been recently proposed but no 
general agreement has been achieved. Most of the latterly published studies have based their method on defining 
thresholds that act as a discriminant for  TMTV2, some of which are based on standardized uptake value (SUV) 
obtained in  [18F]FDG PET/CT3. Both absolute and relative thresholds are frequently used, although more com-
plex algorithms including iterative thresholds that correct partial-volume effect (PVE), and adaptive cut-offs 
based on lesion-to-background ratio are also being  employed4.
Finding a common unified method is necessary for forthcoming studies which could allow comparisons 
between institutions leading to optimal patient management within medical  centers5. Software tools can be 
a source of discrepancy between obtained TMTV values due to internal segmentation algorithms. However, 
threshold choice within the software has been proven to influence the TMTV, though no significant differences 
between predicted prognosis have been  found6. Therefore, contrasting the effect of software packages and dif-
ferent thresholds on the TMTV estimation could help predict future patients outcome, basing their survival 
foreshadow on the parameters given by the chosen  methodology7. Despite the availability of advanced algorithms 
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for the delimitation of the TMTV, the only universal multivendor methods are the simple ones based on defined 
thresholds, as recommended for a general oncological case in the EANM 2.0  protocol8.
The aim of this study was to delimit TMTV in Hodgkin lymphoma patients (Ann-Arbor stage I and II) 
on baseline  [18F]FDG PET/CT acquisitions. Contouring was performed using different software tools (BI and 
 LIFEx6,9) and TMTV discrimination was achieved using SUV based thresholds (2.5 SUV, 41%  SUVmax, and 50% 
 SUVmax). Both potential sources of bias were analyzed to compare TMTV reproducibility. The effect of multiple 
and single ROI drawing procedures in multiple lesion affected patients was also studied. Research also focused 
on the effect of evaluated parameters on the prognosis of the disease to predict patient outcome.
Material and methods
This manuscript has been revised for its publication by the Clinical Research Ethics Committee of Bellvitge 
University Hospital. Written informed consent was waived by this Committee, as it was a retrospective analysis 
of our usual everyday work. The data of the patients were anonymized for the purposes of this analysis. The 
confidential information of the patients was protected according national normative.
Patients’ characteristics and image acquisition. Out of a database of 116 HL affected patients within 
our institution, only 76 were compared and analyzed. The 40 remaining were excluded due to DICOM loading 
failure (6), Ann-Arbor stages III–IV (12), interim or post excision (4), missing data in image acquisition (4) 
and under nuclear medicine specialist criteria (14), which included no follow up (3), relapse (5), and misclas-
sified patients (6). Patient characteristics including bulky mass for lesions such > 10  cm and histologic sub-
types are shown in Table 1. The most frequent treatment in the evaluated patients was ABVDx4 ± RT, however, 
the therapies varied after deciding the therapeutic plan in a multi-disciplinary committee according to clinical 
characteristics, baseline risk factors, the interim PET study and also patients’ tolerance to chemotherapy. Those 
included ABVDx2 ± RT, ABVDx3 ± RT, ABVDx6 ± RT, ABVDx8 ± RT and some even escalated to BEACOPP. 
Due to the retrospective nature of the study and the non-homogeneity of the treatments administered, with a 
multitude of subgroups, the analysis of these data has not been performed. PET/CT images were acquired in 
a Discovery ST (D-ST) or Discovery IQ (D-IQ) PET/CT (GE Healthcare, Waukesha, WI) at 70 ± 15 min after 
intravenous administration of 2.3–3.7 MBq/kg of [18F]FDG, being mandatory to have a blood glucose level 
below 10  mmol/L at the time of the radiopharmaceutical injection. The scanning protocol included a torso 
imaging (from the skull base to mid-thigh), with arms raised whenever possible. Studies from D-ST were recon-
structed with a VPHD algorithm with 21 subsets and 2 iterations, and a 6.0 mm Gaussian filter, using a matrix 
of 128 × 128. D-IQ images were reconstructed with a VPHD-S (VPHD with a point-spread function correction) 
algorithm with 12 subsets and 4 iterations, and a 4.8 mm Gaussian filter, using a matrix of 256 × 256. Effect of 
distinct spatial resolution will be minimum for localized lymphoma as tumors are big enough. The effect of scan-
ner choice was studied contrasting potential differences between D-ST and D-IQ scanners using a paired t test 
before mixing both samples.
Determination of TMTVs. The TMTV were delimited in both software by a medical physicist and super-
vised and approved by a specialist nuclear medicine physician. Multiple physician supervision was not consid-
ered essential due to the use of automatic methods for localized lesions. To delimit TMTV with the BI software 
using a single region of interest (ROI), a ROI involving all focuses of  [18F]FDG activity was drawn in one of the 
slices of each patient avoiding physiological uptake. Despite the difficulty of this procedure, since in many of the 
Table 1.  Patients’ characteristics.
Mean Median Range
Age (years) 37.5 35 16–87
Follow-up (months) 49.9 51.5 3–104




D-ST PET/CT 69 90.8
D-IQ PET/CT 7 9.2
Ann-Arbor stage I 6 7.9
Ann-Arbor stage II 70 92.1
Bulky mass 7 9.2
Mediastinal 15 19.7
Histological subtypes
Nodular sclerosis 54 71.0
Mixed cellularity 10 13.2
Lymphocyte rich 2 2.6
Lymphocyte depletion 10 13.2
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patients the injured region was at a different depth in the frontal axis than the physiological uptakes from the 
heart or lymph nodes, we were able to perform the analysis with precision by the definition of the single ROI in 
most of the cases. It was then extrapolated to the limiting slices obtaining a volume of interest (VOI) to which 
2.5, 41% and 50% cut-offs were applied (Fig. 1). The software automatically selected and highlighted the voxels 
with a SUV value over the threshold and calculated the TMTV,  SUVmean,  SUVmax, and  SUVpeak. Total lesion gly-
colysis (TLG) was later calculated for each threshold as the product of  SUVmean and TMTV. The procedure for 
LIFEx was performed similarly but the ROIs were modified slice by slice, detecting only tumoral regions and 
avoiding physiological uptake healthy organs. The mentioned thresholds were applied to the defined VOI and 
the same parameters were calculated.
There are two different approaches to segment the TMTV. A single ROI covering all avid regions can be 
drawn as explained in the previous paragraph, but there is a second and more laborious approach consisting in 
performing individual multiple ROIs for each lesion. Using only the BI software we studied the effect of both 
different methodologies in the definition of the TMTV for those patients who had multiple lesions.
Data and statistical analysis. For the study and comparison of TMTV values between software and 
thresholds, as well as for TLG and  SUVmean values, due to non-normal distributions data were log-transformed. 
The statistical analysis and graphs were done using those results. TMTV and TLG values were expressed quanti-
tatively as their mean and their median, specifying the range of values within the data set.
TMTV,  SUVmean, TLG,  SUVmax, and  SUVpeak values were analyzed for both software using the mentioned rela-
tive and absolute thresholds. Latter comparisons were made. Multiple and single ROI drawing consequences on 
volume contouring were studied and compared between software tools and thresholds.
Differences and correlation between the two studied samples were displayed using Bland–Altman analysis 
and Pearson coefficient respectively, and their corresponding distributions of data using box plots showing the 
p-value were obtained in the paired sample double tailed t test for all the parameters mentioned above (TMTV, 
 SUVmean, TLG,  SUVmax, and  SUVpeak).
Study of the effect of PET machinery was analyzed using the independent (non-paired) sample t test applied 
to the previous normalized data of TMTV using logarithms. Comparison was performed according if imaging 
was acquired with D-ST or D-IQ.
Progression-free survival (PFS) was also drawn including both deaths and lymphoma progression. For both 
software packages, survival curves using the Kaplan–Meier estimator were calculated for each threshold com-
paring two subgroups split by the TMTV cut-off found in the Receiver Operating Characteristics (ROC) curve. 
This value was determined by the Youden index according to the optimal sensitivity and specificity based on the 
comparison of two related TMTV samples. ROC curves described the evolution of HL patients and predicted 
treatment failure in terms of the Area Under the Curve (AUC). For software comparison, ROC curves were 
also drawn using the same threshold to show the differences between both TMTV cut-offs and to contrast HL 
progression.
Results
Comparison between both PET machines D-ST and D-IQ showed no statistical significance in TMTV values nei-
ther for BI nor LIFEx (p = 0.26 and p = 0.27 for 2.5, p = 0.07 and p = 0.16 for 41%, and p = 0.09 and p = 0.23 for 50%, 
respectively). All  SUVmax values were exactly the same when comparing software packages and thresholds in all 
of the studied cases.  SUVpeak values between different thresholds within BI were statistically significant (p < 0.02) 
and for LIFEx exact coincidence could be observed. For 2.5 and 41% thresholds the comparison between BI 
and LIFEx showed significant differences (p < 0.0001) while for 50% less differences could be seen (p = 0.22).
TMTV. Statistical significance could be observed between TMTV obtained using different thresholds 
 (TMTV2.5,  TMTV41%, and  TMTV50%) within the same software (p < 10–20), as well as when comparing both 
software applying the same threshold for 41% and 50% (p < 0.02). However, fewer differences could be found in 
2.5 (p = 0.09). A strong correlation was obtained in the comparison of 41% and 50% TMTV (r > 0.97) for both 
software tools, and when comparing BI with LIFEx for the different thresholds  TMTV2.5 (r = 0.997),  TMTV41% 
(r = 0.92) and  TMTV50% (r = 0.89), as shown in the respective Bland Altman analyses (Fig. 2).
Figure 1.  Threshold comparison using BI, (A) baseline, (B) 2.5 SUV, (C) 41%  SUVmax and (D) 50%  SUVmax.
4
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:12590  | https://doi.org/10.1038/s41598-020-69577-9
www.nature.com/scientificreports/
Outliers displayed in the previous graph were acquired as it follows: 7 outliers (6 ST-AC and 1 IQ-AC) for the 
2.5 threshold, 4 outliers (3 ST-AC and 1 IQ-Q.Clear) for the 41%, and 3 outliers (ST-AC) for the 50%. Obtained 
values performing the study considering the whole set of patients and using BI and LIFEx as contouring software 
are displayed in Table 2.
Multiple ROI study. This study was performed with those patients who had multiple affected regions within 
their body. For this concrete set of patients, when contrasting the effect of drawing single or multiple ROIs in 
BI compared to the TMTV obtained in LIFEx single ROI drawing, more similarities to LIFEx were found when 
using BI multiple ROIs for 2.5 (r = 0.995, p = 0.33) than when using single ones (r = 0.997, p = 0.09) as shown 
in Table 3. Nonetheless, for 41% and 50% statistical significance was found in the use of single ROIs (r = 0.92, 
p = 0.006 and r = 0.89, p = 0.013), as well as when using multiple ones (r = 0.92, p = 0.0004 and r = 0.96, p < 10–5).
For the 2.5 cut-off, more significant differences between single and multiple procedures were found for BI 
(r = 0.9994, p = 0.07) than for LIFEx (r = 0.995, p = 0.33). Using BI, for 41% (r = 0.94, p = 0.04) and 50% (r = 0.98, 
p = 0.007) statistical significance between compared values was obtained, as well as for LIFEx (r = 0.92, p = 0.0004, 
and r = 0.96, p < 10–5, respectively). The highest correlations were found between LIFEx single ROI and BI multiple 
ROI (Fig. 3), showing the effect of the use of multiple ROI drawings in BI compared to single ROI drawings in 
both BI and LIFEx, respectively.
When comparing  SUVmean values obtained with BI and LIFEx, excellent correlation between them was found 
for the 2.5 cut-off (r = 0.996, p = 0.70), as well as for 41% (r = 0.97, p = 0.005) and 50% (r = 0.96, p = 0.02). No 
significant differences were observed in the analysis of the 2.5 cut-offs (Fig. 4).
Figure 2.  Bland Altman analysis for TMTV obtained using different thresholds. Comparison between software 
tools BI versus LIFEx. SUV > 2.5 threshold delimitation (A), SUV > 41% SUVmax (B) and SUV > 50% SUVmax 
(C). Values outside the agreement region in dashed grey lines were marked as black cross outliers but were not 
discarded from the analysis.
Table 2.  Study for the whole set of patients without considering the number of lesions they had. Contouring 
performed using BI and LIFEx. P values compared the mentioned pair of data.
Threshold Study type
BI  (cm3) LIFEx  (cm3) p value
Mean Median Range Mean Median Range BI vs LIFEx
2.5 Whole set 208.46 137.11 9–1,102 208.45 139.10 8–1,038 0.09
41% Whole set 69.31 52.71 8–461 62.24 50.66 3–462 0.006
50% Whole set 44.29 31.20 4–384 40.00 27.87 1–384 0.001
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Table 3.  Single ROI study vs multiple ROI study. For the multiple lesion affected patients, values obtained 
in multiple ROI drawing in BI were compared to the ones obtained in single ROI drawing in LIFEx. P values 
compared the mentioned pair of data.
Threshold Study type
BI  (cm3) LIFEx  (cm3) p value
Mean Median Range Mean Median Range BI vs LIFEx
2.5
Single ROI 250.96 203.41 9–805 249.84 189.80 9–804 0.11
Multiple ROI 247.85 197.74 9–794 – – – 0.07
41%
Single ROI 96.21 75.90 13–461 86.66 72.08 13–462 0.004
Multiple ROI 101.90 76.52 17–470 – – – 0.04
50%
Single ROI 63.10 44.20 8–384 57.82 43.62 8–384 0.004
Multiple ROI 66.06 47.14 11–393 – – – 0.007
Figure 3.  Multiple ROI study for the SUV > 2.5 threshold. Bland Altman analysis and Box Plot displaying the 
comparison of TMTV obtained using single ROI in BI and sum of multiple ROIs in BI (A, C) and LIFEx single 
ROI vs sum of multiple ROIs in BI (B, D).
Figure 4.  SUVmean comparison using both software applying 2.5 SUV threshold. Limits of agreement are also 
displayed, as well as outliers marked with a black cross.
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The mean and median TLG values for BI were  TLG2.5 1,073.64 and 694.47 cm3 (range 27–6,028),  TLG41% 
522.81 and 327.93 cm3 (range 34–4,689), and  TLG50% 380.86 and 214.80 cm3 (range 20–4,095). For LIFEx these 
values were 1,071.39 and 670.52 cm3 (range 26–6,031), 499.69 and 289.78 cm3 (range 13–4,643), and 363.88 and 
211.13 cm3 (range 3–4,095), respectively. Similarities between both software could be found according to the 
studied cut-offs,  TLG2.5 showed a slightly higher correlation (r = 0.9998, p = 0.03) than  TLG41% (r = 0.97, p = 0.008) 
and  TLG50% (r = 0.95, p = 0.015) (Fig. 5).
Progression‑free survival. Optimal TMTV cut-offs found in ROC curves using 2.5, 41% and 50% thresh-
olds for BI and LIFEx were 101.71 cm3 and 101.30 cm3, 63.18 cm3 and 59.07 cm3, and 41.86 cm3 and 26.41 cm3, 
respectively. More similarities were found between both software tools using 2.5 SUV threshold (Fig. 6).
AUC values for BI according to the mentioned thresholds (2.5, 41% and 50%) were 0.70, 0.64 and 0.60. For 
LIFEx obtained AUC were 0.70, 0.68 and 0.62, respectively. Discrimination performed by the model was accept-
able: around 70% of the patients were correctly classified.
Highest AUC was obtained for the 2.5 threshold when comparing both software. No differences in prognosis 
were observed in none of them.
PFS showed similarities between TMTV discriminated values for BI and LIFEx for all considered thresholds 
(2.5 p = 0.11 and p = 0.010, 41% p = 0.12 and p = 0.09, and 50% p = 0.25 and p = 0.26) (Fig. 7).
However, despite observing visually distinct curves, no significant differences were found between them due 
to the low number of patients with a TMTV bigger than the cut-off. Moreover, some patients did not have long 
enough follow-up, which could affect the behavior of such curves.
Discussion
Response-adapted therapy using  [18F]FDG PET/CT imaging at baseline (early detection) and interim has been 
proven to be a valuable predictor for disease prognosis in lymphoma  patients2,10,11. The implementation of such 
methodology could be useful to avoid overtreatment in patients whose chemotherapy results in long-term PFS, 
as well as overall survival (OS)12. This could also help medical institutions to reach optimal patient management 
with customized treatments. SUV-based assessment on  [18F]FDG PET/CT images has been shown to improve 
the prediction of patient outcome compared to visual analysis, due to interim PET false-positive results in  HL3. 
However, no general agreement on the choice of threshold and software tools has been reached, meaning inter-
institutional comparisons are hard to develop and no consensus on common clinical protocol has been attained. 
Therefore, different methodologies have been studied, using fixed and relative thresholds and different software 
tools to achieve successful TMTV delimitation in HL patients. Comparisons between them have been performed 
to find the best reproducibility between TMTV calculations; the effect of potential sources of discrepancy in 
patient outcome prediction has also been analyzed.
We restricted ourselves to localized lymphoma since we aimed to take a relatively homogeneous sample to 
avoid excessive multiple data correlation due to the heterogeneity in localized and advanced stage patients. If 
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stage III–IV had been also included, a much extensive number of variables and considerations would have been 
needed. Non-localized lymphoma involves lesions which cannot be segmented using a regular threshold. The 
effect of different treatment regimens should be explored in future studies.
Figure 6.  ROC curves comparing both software tools when using each threshold. Strong similarities are shown 
in 2.5 threshold. BI vs LIFEx 2.5 (A), BI vs LIFEx 41% (B), and BI vs LIFEx 50% (C). BI is displayed in blue and 
LIFEx in orange.
Figure 7.  Kaplan–Meier analysis showing the predicted patient outcomes according to the TMTV cut-offs 
found in ROC for a  SUV2.5 threshold in (A) BI and in (B) LIFEx.
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Although multiple physician supervision was not studied in the present work, as we relied in automatic 
methods for localized lesions, further research should be conducted on physician reproducibility especially in 
non-localized lymphoma.
In the present study,  SUV2.5 thresholds overestimate TMTV and SUV values due to its segmentation sim-
plicity. This statement is based mostly on visual assessment of the affected region compared to the one selected 
by the threshold. In many of the analysed patients the 2.5 threshold chose a wider region as lymphoma than 
expected, including some parts which were not affected by the disease. Absolute thresholds such as 2.5 tend to 
miss information from background activity and select voxels with intensity over a fixed value regardless of the 
lesion-to-background ratio, meaning that if voxels in lesion contour have a similar uptake to background voxels, 
these will be likely considered as a tumoral region.
The relative threshold approach is defined by assuming that those voxels having an intensity of at least a des-
ignated percentage of  SUVmax will be part of  TMTV13. High lesion-to-background ratio cases result in precise 
tumor delimitation. However, in patients whose lesions have low intensity, usage of relative thresholds can lead 
to overestimation due to a systematic lack of distinction between lesion and background detections. Despite 
that, if local uptakes inside the TMTV that are significantly higher compared to the rest of the metabolic active 
region are present, underestimation of the TMTV will have a high chance of occurring.
The 41%  SUVmax threshold allows a much wider range of uptake values to be detected than 50%  SUVmax when 
high intensities are being considered. The second mentioned cut-off misses most of the TMTV and only takes 
the surroundings of the region where  SUVmax is found. Nonetheless, when  SUVmax is not remarkably high, dif-
ferences between both thresholds are only significant in bulky tumors.
Contouring was based on delimiting the ROI that included as many tumoral uptakes as possible and avoided 
all physiological detections. ROI drawing depended mostly on the software tool. BI had more limitations in the 
drawing process because the region was chosen on a single slice and then extrapolated to the limiting slices; 
limits were displayed in z-axis for the axial view. Those limitations were due to the software tool as the draw-
ing of our region was performed in only one of the slices which implied that in some of the cases physiological 
uptake areas were incorrectly detected as disease. This issue affected the correct discrimination of tumoral areas 
in some of the patients where lesions laid close to healthy organs with  [18F]FDG uptake. In these situations, the 
use of multiple ROI to delimit tumoral areas avoided the misdetection of physiological activity. Compared to 
LIFEx, this was no longer an issue because of the precise painting tools available for contouring and the existence 
of a region eraser for those areas that had been mistakenly chosen as lymphoma. Drawing was therefore more 
precise but slower to perform since ROI delimitation was modified slice by slice. To obtain the first indicative 
delimitation of the region in BI took us approximately 10 min, while for LIFEx implied a minimum of 15 min 
and up to 30 min. This is displayed as an average of the employed time, but it also depended on the closeness of 
lesions to physiological uptakes and the extensivity of the affected region. Since the data set included 76 patients, 
the difference of time required to perform the contouring between both software was large enough to consider 
LIFEx a slower method. Maximum accuracy for contouring took more time but oscillated depending on the 
patient, especially for multiple lesion affected ones; however, all healthy organs could be avoided using a single 
ROI since physiological detections were scarcely displayed in images.
Finding the best methodology would mean achieving exceptional reproducibility between TMTV values, 
as well as finding similarities between SUV parameters and TLG, which are good indicators of tumor activity.
In the single ROI study, software comparison between BI and LIFEx showed good reproducibility for  TMTV2.5 
compared to  TMTV41% and  TMTV50% due to the use of the same segmentation criteria and the absence of 
algorithm complexity. However, 41% and 50% thresholds showed similarities within the software in single ROI 
studies. 41% and 50%  SUVmax thresholds showed an excellent correlation between them when using the same 
software for both BI and LIFEx; this was due to BI single ROI mistaken delimitation which overestimated the 
tumoral region when using  SUV2.5 threshold that differed from the TMTV obtained with 41% and 50%.
Multiple ROI study showed a better correlation between LIFEx single and BI multiple than LIFEx single and 
BI single. Moreover, when comparing LIFEx single and BI multiple with BI single and BI multiple, a stronger 
correlation was found between different software tools. This could be due to the fact that BI single ROI draw-
ing had mistakenly taken healthy tissue as the tumoral region in some patients where lesions were close to 
physiological detections. LIFEx single contouring and BI multiple ROI drawing did not take these as part of the 
TMTV, which resulted in reliable TMTV delimitation. Therefore, the best reproducibility of TMTV values in 
all performed studies was found for LIFEx single ROI and BI multiple ROI drawing, regardless of the applied 
threshold. Reproducibility was tested comparing the results obtained using different methodologies including 
software tool, threshold and multiple or single ROI study choice. High reproducibility was considered for those 
studies which showed strong similarities between the obtained values, basing our criteria on the ability of rep-
licating the data obtained under different methods.
The  SUVmean values differed between thresholds within the same software tool but took similar values in 41% 
and 50% comparison. A strong correlation was found between obtained values using different software. Hence, 
the comparison of calculated TLG values using the same threshold showed a high correlation as well. However, 
 TMTV2.5 having the best reproducibility resulted in the strongest correlation for  TLG2.5 in software comparison.
The  SUV2.5 threshold showed higher values for TMTV and SUV parameters, as well as for TLG calcula-
tion. This was due to the mentioned overestimation intrinsic to the cut-off caused by arbitrary segmentation 
algorithms. Consequently, optimal metabolic tumor volume predicted by ROC curves for 2.5 was also greater 
than the obtained using 41% and 50% thresholds. Nevertheless, measured differences in TMTV did not show 
an impact on computed survival curves.
Similarly Cottereau et al.14 compared different adaptive thresholds to the  SUVmax based ones, and concluded 
that the definition of the TMTV is not crucial to obtain an initial good prognostic value for peripheral T cell 
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lymphoma. Our results are consistent with the idea that an accurate definition of the TMTV is not as important 
as other factors in general case mixing different stages and treatment protocols.
Furthermore, in previous studies Kanoun et al.6 used 2.5, 41%, 125% liver  SUVmax and 140% liver  SUVmax, 
and found optimal cut-offs for prediction of treatment failure according to the mentioned thresholds and, find-
ing cut-offs and AUC values for 2.5 and 41% higher than those obtained in our study. However, patient selec-
tion can affect TMTV depending on the Ann-Arbor stage. Kanoun et al. considered stages I to IV. Song et al. 
performed their study with patients at stages I–II and their optimal cut-offs using 2.5 threshold were only a bit 
higher than the obtained in our study using 2.511. Another factor influencing these discrepancies could be the 
number of patients with bulky tumors, which would lead to higher TMTV detection; Song et al. had 26 bulky 
patients while we only accounted 7.
Regarding our results, further work should be done assessing the impact of different acquisition settings and 
machinery choice, as there could be an impact on MTV measurements.
Our study did not consider the use of adaptive algorithms in TMTV discrimination. Only fixed and relative 
thresholds available within the software tool were analyzed. Erdi et al. found that adaptive thresholds worked 
optimally for small tumors. For lesions > 4 cm3, image segmentation converged to fixed thresholds from 36 to 
44%15. Patient database only included HL individuals from our institution. Also, we did not include modern 
algorithms as Q.Clear which could have a bigger impact on the delimitation of the  TMTV16,17. Forthcoming stud-
ies including patient sets from different medical centers could allow a deeper analysis of distinct methodologies, 
which could lead to a future unification of TMTV delimitation method.
Conclusions
Unification of methodologies in TMTV delimitation needs to be achieved in order to improve patient manage-
ment in medical centers despite the absence of differences in survival prediction regarding each studied method.
Our study suggests that TMTV based on SUV 2.5 threshold is the most reproducible and robust parameter 
under the choice of a software tool or delimitation method; the overestimation of TMTV seems to be desirable 
rather than underestimation in terms of reproducibility. Best reproducibility regarding software tools was found 
for LIFEx single ROI and for BI multiple ROI drawing, regardless of the applied threshold.
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